Method for predicting hypertensive disorders of pregnancy by combining D-dimer with alpha fetoprotein and free[beta]-hCG in maternal serum during mid-pregnancy

Abstract

The invention discloses a method for hypertensive disorders of pregnancy by combining D-dimer with alpha fetoprotein and free[beta]-hCG in maternal serum during mid-pregnancy. The method comprises thesteps of dividing pregnant women into three case groups and a control group according to the existence or absence of gestational hypertension GH, preeclampsia PE and severe preeclampsia group SPE; detecting the levels of D-dimers, AFP (alpha fetoprotein) and free[beta]-HCG of the four groups of pregnant woman serum specimens, and representing the measured levels of the D-dimers, the AFP and the free[beta]-HCG by the median multiples MoM of the weight and the gestational weeks; and comparing median multiple MoM distribution conditions, and constructing a risk calculation model by using MOM values in combination with the weight and the gestational weeks. The method has the beneficial effects that the risk calculation model constructed by calibrating MOM values of the D-dimer, the AFP and the free[beta]-HCG in serum of the pregnant woman in combination with the weight and the gestational weeks has relatively high sensitivity and specificity when being used for screening the hypertensivedisorders of pregnancy HDP, and can become a new marker for predicting the hypertensive disorders of pregnancy HDP.

Description

technical field [0001] The invention relates to the field of medical detection, and mainly relates to a method for predicting hypertensive disorders during pregnancy by combining D-dimer of maternal serum in the second trimester with alpha-fetoprotein and freeβ-hCG. Background technique [0002] D-D is the smallest fragment of plasmin-mediated fibrin cleavage. In normal pregnancy, the concentration of D-D gradually increases with the progress of pregnancy[1-2]. It is the most valuable laboratory tool for clinical conditions, including the diagnosis of venous thromboembolism (VTE), pregnancy monitoring, and the diagnosis / monitoring of disseminated intravascular coagulation (DIC) [3]. During the second trimester (15 weeks to 20 weeks and 6 days) maternal serum prenatal screening markers alpha-fetoprotein (alpha-fetoprotein, AFP) and free human chorionic gonadotropin β subunit (free β subunit of human chorionic gonadotropin, Free β-hCG) Combined detection is widely used in pre...

AI Technical Summary

Problems solved by technology

The previous results of this study showed that the high level of AFP MoM in the serum of women in the second trimester is a risk factor for PE, which can predict the possibility of PE in late pregnancy, but its detection sensitivity is low, and the value of screening PE alone is limited, and it needs to be combined with other markers[ 11]

Images